HLX10-006-GCneo (NCT04139135) is a phase 3 clinical trial comparing serplulimab plus SOX to placebo plus SOX in the perioperative setting for PD-L1 CPS ≥5 GC patients. The gene discussed is CD274; the disease is gastric cancer.